Sunshine Heart benefits from negative NEJM article, says Piper Jaffray Piper Jaffray views the NEJM article relating to an increase in clotting after implantation of Thoratec's (THOR) Heartmate II as mildly positive for Sunshine Heart (SSH). Piper believes attention to LVAD thrombosis rates could help remind the medical and investment community of the potential for a low clotting rate with the Sunshine Heart device. The firm reiterates an Overweight rating on Sunshine Heart with a $14 price target.
News For SSH;THOR From The Last 14 Days
Check below for free stories on SSH;THOR the last two weeks.